(Q46495618)

English

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome

scientific article published in May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

metabolic syndrome

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Giuseppe Derosa

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Arrigo F. Cicero

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Sibilla A T Salvadeo

5

object named as

Sibilla Salvadeo

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

8

object named as

Ilaria Ferrari

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Leonardina Ciccarelli

4

object named as

Leonardina Ciccarelli

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Mario N Piccinni

3

object named as

Mario N Piccinni

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Emmanouil Peros

6

object named as

Emmanouil Peros

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Antonio Vittorino Gaddi

2

object named as

Antonio V Gaddi

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

7

object named as

Morena Ghelfi

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

25

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

637-645

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Atherothrombosis, inflammation, and diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Dietary glycemic load and atherothrombotic risk

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Determination of total serum insulin (IRI) in insulin-treated diabetic patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Fat cell function and fibrinolysis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Combining sulfonylureas and other oral agents

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Clinical review of glimepiride

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Thiazolidinediones -- some recent developments

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.25.5.637.63587

21 January 2018

Identifiers

10.1592/PHCO.25.5.637.63587

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15899724

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46495618&oldid=2114401627"